Pasquale Mone1,2,3, Angela Lombardi1, Jessica Gambardella1,4, Antonella Pansini2, Gaetano Macina2, Maria Morgante2, Salvatore Frullone2, Gaetano Santulli1,4,5. 1. Department of Medicine, Einstein-Sinai Diabetes Research Center, The Fleischer Institute for Diabetes and Metabolism, Einstein Institute for Aging Research, Albert Einstein College of Medicine, New York, NY. 2. Azienda Sanitaria Locale Avellino, Avellino, Italy. 3. Department of Preventive Medicine, University of Campania "Luigi Vanvitelli," Naples, Italy. 4. International Translational Research and Medical Education (ITME) Consortium and Department of Advanced Biomedical Sciences, "Federico II" University, Naples, Italy. 5. Department of Molecular Pharmacology, Wilf Family Cardiovascular Research Institute, Institute for Neuroimmunology and Inflammation, Albert Einstein College of Medicine, New York, NY.
Abstract
OBJECTIVE: To assess whether the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin improves cognitive impairment in frail older adults with diabetes and heart failure with preserved ejection fraction (HFpEF). RESEARCH DESIGN AND METHODS: We designed a prospective study to assess cognitive and physical function in consecutive frail older adults with diabetes and HFpEF, comparing the effects of empagliflozin, metformin, and insulin. RESULTS: A total of 162 frail older adults with HFpEF and diabetes successfully completed the study. Montreal Cognitive Assessment scores at baseline and after 1 month were 19.80 ± 3.77 vs. 22.25 ± 3.27 (P < 0.001) in the empagliflozin group, 19.95 ± 3.81 vs. 20.71 ± 3.56 (P = 0.26) in the metformin group, and 19.00 ± 3.71 vs. 19.1 ± 3.56 (P = 0.81) in the insulin group. A multivariable regression analysis confirmed the beneficial effects of empagliflozin. Additionally, we observed a marked amelioration of physical impairment, assessed by the 5-m gait speed test, in the empagliflozin and metformin groups but not in the insulin group. CONCLUSIONS: This study is the first to show significant beneficial effects of the SGLT2 inhibitor empagliflozin on cognitive and physical impairment in frail older adults with diabetes and HFpEF.
OBJECTIVE: To assess whether the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin improves cognitive impairment in frail older adults with diabetes and heart failure with preserved ejection fraction (HFpEF). RESEARCH DESIGN AND METHODS: We designed a prospective study to assess cognitive and physical function in consecutive frail older adults with diabetes and HFpEF, comparing the effects of empagliflozin, metformin, and insulin. RESULTS: A total of 162 frail older adults with HFpEF and diabetes successfully completed the study. Montreal Cognitive Assessment scores at baseline and after 1 month were 19.80 ± 3.77 vs. 22.25 ± 3.27 (P < 0.001) in the empagliflozin group, 19.95 ± 3.81 vs. 20.71 ± 3.56 (P = 0.26) in the metformin group, and 19.00 ± 3.71 vs. 19.1 ± 3.56 (P = 0.81) in the insulin group. A multivariable regression analysis confirmed the beneficial effects of empagliflozin. Additionally, we observed a marked amelioration of physical impairment, assessed by the 5-m gait speed test, in the empagliflozin and metformin groups but not in the insulin group. CONCLUSIONS: This study is the first to show significant beneficial effects of the SGLT2 inhibitor empagliflozin on cognitive and physical impairment in frail older adults with diabetes and HFpEF.
Authors: Karen R Siegel; Mohammed K Ali; Xilin Zhou; Boon Peng Ng; Shawn Jawanda; Krista Proia; Xuanping Zhang; Edward W Gregg; Ann L Albright; Ping Zhang Journal: Diabetes Care Date: 2020-07 Impact factor: 19.112
Authors: Pasquale Mone; Antonella Pansini; Salvatore Frullone; Antonio de Donato; Veronica Buonincontri; Paolo De Blasiis; Anna Marro; Maria Morgante; Antonio De Luca; Gaetano Santulli Journal: Eur J Intern Med Date: 2022-03-14 Impact factor: 7.749
Authors: Antonella Pansini; Angela Lombardi; Maria Morgante; Salvatore Frullone; Anna Marro; Mario Rizzo; Giuseppe Martinelli; Eugenio Boccalone; Antonio De Luca; Gaetano Santulli; Pasquale Mone Journal: Front Endocrinol (Lausanne) Date: 2022-04-14 Impact factor: 6.055
Authors: Sanne Kuipers; Jacoba P Greving; Hans-Peter Brunner-La Rocca; Rebecca F Gottesman; Robert J van Oostenbrugge; Nicole L Williams; Geert Jan Biessels; L Jaap Kappelle Journal: Int J Cardiol Heart Vasc Date: 2022-10-10